Comparison of Intravitreal Bevacizumab and Intravitreal Diclofenac in the Treatment of Diabetic Macular Edema: a 6-month Follow-up
Medical hypothesis discovery and innovation in ophthalmology,
Vol. 6 No. 3 (2017),
30 October 2017
Abstract
The aim of this study was to compare the effect of intravitreal diclofenac, a non-steroidal anti-inflammatory drug (NSAID), with that of bevacizumab, a well-known anti-vascular endothelial growth factor (VEGF) drug, in the treatment of diabetic macular edema (DME). Diclofenac was chosen in this study because it has both features of NSAIDs and corticosteroids by inhibiting the cyclooxygenase (COX) and lipoxygenase pathways, respectively. In this non-randomized comparative interventional case series, 64 eyes from 32 patients with bilateral naïve DME were selected and every eye was randomly assigned to intravitreal injection of bevacizumab (IVB) or diclofenac (IVD). After exclusion of some patients because of short follow-up duration or less than two intravitreal injections, finally, 52 eyes from 26 patients were analyzed. Of those, 26 eyes received 500 µg/0.1 mL IVD and 26 eyes received 1.25 mg IVB. After 6 months of follow-up, the results indicated that visual acuity was significantly improved from 0.50 ± 0.13 in IVB and 0.52 ± 0.12 LogMAR in IVD at baseline to 0.2 ± 0.1 and 0.29 ± 0.07, respectively. Central macular thickness (CMT) and macular volume were measured based on spectral-domain optical coherence tomography (OCT) at month 1, 3, and 6. Both groups showed a significant reduction in CMT and macular volume from baseline but there was no significant difference between the IVB and IVD groups. Interestingly, IVD, but not IVB, decreased intraocular pressure (IOP), which is a desirable effect. There was no serious complication due to injections. This study sheds light into the long-term effects of NSAIDs and may support the idea that inflammation suppression by NSAIDs may have the same results as anti-VEGF administration.ÂReferences
Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol. 2010;88(3):279-91. DOI: 10.1111/j.1755-3768.2008.0 1501.x PMID: 20222885
Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146-51. DOI: 10.1016/j.ophtha.2010.08.016 PMID: 20855114
Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006;26(9):999-1005. DOI: 10.1097/01.iae.0 000247165.38655.bf PMID: 17151486
Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113(9):1533-8. DOI: 10.1016/j .ophtha.2006.02.065 PMID: 16828501
Arevalo JF. Diabetic macular edema: Current management 2013. World J Diabetes. 2013;4(6):231-3. DOI: 10.4239/wjd.v4.i6.231 PMID: 24379911
Bandello F, Casalino G, Loewenstein A, Goldstein M, Pelayes D, Battaglia Parodi M. Pharmacological approach to diabetic macular edema. Ophthalmic Res. 2014;51(2):88-95. DOI: 10.1159/000356693 PMID: 24356667
Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002;16(3):438-40. DOI: 10.1096/fj.01-0707fje PMID: 11821258
Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des. 2004;10(27):3331-48. PMID: 15544519
Monnier Y, Zaric J, Ruegg C. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy. 2005;4(1):31-8. PMID: 15720233
Alam CA, Seed MP, Willoughby DA. Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac in combination with hyaluronan in mice. J Pharm Pharmacol. 1995;47(5):407-11. PMID: 7494192
Seed MP, Freemantle CN, Alam CA, Colville-Nash PR, Brown JR, Papworth JL, et al. Apoptosis induction and inhibition of colon-26 tumour growth and angiogenesis: findings on COX-1 and COX-2 inhibitors in vitro & in vivo and topical diclofenac in hyaluronan. Adv Exp Med Biol. 1997;433:339-42. PMID: 9561165
Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112(11):1916 e1-7. DOI: 10.1016/j.ophtha.2005.06.009 PMID: 16171868
Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging. 2003;34(5):386-90. PMID: 14509462
Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004;122(3):336-40. DOI: 10.1001/ archopht.122.3.336 PMID: 15006845
Hogewind BF, Zijlstra C, Klevering BJ, Hoyng CB. Intravitreal triamcinolone for the treatment of refractory macular edema in idiopathic intermediate or posterior uveitis. Eur J Ophthalmol. 2008;18(3):429-34. PMID: 18465727
Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002;42(1):1-11. PMID: 12189605
Elbendary AM, Shahin MM. Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema. Retina. 2011;31(10):2058-64. DOI: 10.1097/IAE.0b013e31822 a042a PMID: 21765371
Soheilian M, Karimi S, Ramezani A, Peyman GA. Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina. 2010;30(3):509-15. DOI: 10.1097/IAE.0b013e3 181bdfa43 PMID: 19952986
Soheilian M, Rabbanikhah Z, Ramezani A, Kiavash V, Yaseri M, Peyman GA. Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot study. J Ocul Pharmacol Ther. 2010;26(2):199-206. DOI: 10.1089/jo p.2009.0093 PMID: 20307215
Reis Ado C, Vianna RN, Reis RS, Cardoso GP. [Intravitreal injection of ketorolac tromethamine in patients with diabetic macular edema refractory to retinal photocoagulation]. Arq Bras Oftalmol. 2010;73(4):338-42. PMID: 20944936
Maldonado RM, Vianna RN, Cardoso GP, de Magalhaes AV, Burnier MN, Jr. Intravitreal injection of commercially available ketorolac tromethamine in eyes with diabetic macular edema refractory to laser photocoagulation. Curr Eye Res. 2011;36(8):768-73. DOI: 10.3109/02713683.2011.585734 PMID: 2178 0926
Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):1796-806. PMID: 2866759
Diabetic Retinopathy Clinical Research N, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064-77 e35. DOI: 10.1016/j.ophtha.201 0.02.031 PMID: 20427088
Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006;113(10):1706-12. DOI: 10.1016/j.ophtha.2006.0 4.033 PMID: 17011952
Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004;111(2):218-24; discussion 24-5. DOI: 10.1016/j.ophtha.2003.05.037 PMID: 15019365
Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109(5):920-7. DOI: 10.1016/s0 161-6420(02)00975-2 PMID: 11986098
Benhamou N, Massin P, Haouchine B, Audren F, Tadayoni R, Gaudric A. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol. 2003;135(2):246-9. DOI: 10.1016/s0002-9394(02)01938-4 PMID: 12566041
Kothari HV, Lee WH, Ku EC. An alternate mechanism for regulation of leukotriene production in leukocytes: studies with an anti-inflammatory drug, sodium diclofenac. Biochim Biophys Acta. 1987;921(3):502-11. DOI: 10.1016/0005-2760(87)90078-6 PMID: 2822132
Callanan D, Williams P. Topical nepafenac in the treatment of diabetic macular edema. Clin Ophthalmol. 2008;2(4):689-92. PMID: 19668417
Endo N, Kato S, Haruyama K, Shoji M, Kitano S. Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmol. 2010;88(8):896-900. DOI: 10.1111/j.1755-3768.2009. 01582.x PMID: 19725815
Soheilian M, Karimi S, Ramezani A, Montahai T, Yaseri M, Soheilian R, et al. Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial. Int Ophthalmol. 2015;35(3):421-8. DOI: 10.1007/s10792-014-9967-z PMID: 25037243
Shimura M, Nakazawa T, Yasuda K, Nishida K. Diclofenac prevents an early event of macular thickening after cataract surgery in patients with diabetes. J Ocul Pharmacol Ther. 2007;23(3):284-91. DOI: 10.1089/jop.2006.134 PMID: 17593013
Durairaj C, Shah JC, Senapati S, Kompella UB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res. 2009;26(5):1236-60. DOI: 10.1007/s11095-008-9728-7 PMID: 18841448
Ghanbari H, Kianersi F, Sonbolestan SA, Abtahi MA, Akbari M, Abtahi ZA, et al. Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial. Int Ophthalmol. 2017;37(4):867-74. DOI: 10.1007/s10792-016-0335-z PMID: 27624173
Seth A, Ghosh B, Raina UK, Gupta A, Arora S. Intravitreal Diclofenac in the Treatment of Macular Edema Due to Branch Retinal Vein Occlusion. Ophthalmic Surg Lasers Imaging Retina. 2016;47(2):149-55. DOI: 10.3928/23258160-20160 126-08 PMID: 26878448
- Abstract Viewed: 2193 times
- Full Text PDF Downloaded: 1512 times